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ABSTRACT
Objectives: This study assessed the health-related quality of life (HRQOL) of pediatric patients with
type 1 diabetes mellitus (T1DM) and their caregivers.
Methods: CHRYSTAL was an observational cross-sectional study conducted in Spain in 2014 on 275
patients under 18 years old diagnosed with T1DM. Patient/caregiver pairs were stratified by patients’
HbA1c level (7.5% versus <7.5%) and by presence or absence of T1DM complications and/or comor-
bidities. EQ-5D and PedsQL questionnaires were administered to patients and caregivers.
Results: On the EQ-5D, according to caregivers’ perception, 17.7% of children experienced moderate
pain or discomfort, 9.7% suffered problems performing usual activities, and 13.2% demonstrated mod-
erate anxiety or depression. Mean EQ-5D index score was 0.95 and mean visual analog scale (VAS)
score was 86.1. By HbA1c level (7.5% versus <7.5%), mean index scores were 0.94 and 0.95, and
mean VAS scores were 82.8 and 89.2, respectively. Mean index scores were 0.91 for children with com-
plications and/or comorbidities and 0.96 for children without. Mean VAS scores were 83.7 and 87.2,
respectively. HRQOL per the PedsQL tool ranged from 68.1 (ages 2–4) to 73.1 (ages 13–18). EQ-5D
index and VAS scores were significantly correlated (rho ¼ 0.29–0.43) with several age groups of the
PedsQL. EQ-5D scales showed significant moderate correlation between EQ-5D-Y and EQ-5D-3L proxy
VAS score (rho ¼ 0.45; p< .001).
Conclusions: Patients with few complications and controlled HbA1c reported a relatively high HRQOL.
The results suggest that parent-proxy EQ-5D ratings are valid for use as part of an overall health out-
comes assessment in clinical studies of T1DM in pediatric patients.
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Introduction
The prevalence of type 1 diabetes mellitus (T1DM) in Spain is
between 1.1 and 1.4 per 1000 people under 15 years old1.
Previous research has demonstrated that better glycemic
control (lower HbA1c) is associated with higher quality of
life2; however, structured and current information about
health-related quality of life (HRQOL) in the pediatric popula-
tion with T1DM in Spain is very limited3.
It is well known that T1DM care is associated with high
costs and significant family burden in the pediatric popula-
tion4–8. Little is known, however, about overall HRQOL as
perceived by T1DM pediatric patients, particularly those with
an early onset of the disease and their caregivers9.
A growing literature has recently analyzed the HRQOL of
adults with diabetes mellitus10–17. Evaluating HRQOL in
pediatric patients, however, presents several challenges since
young children may not have the cognitive ability to com-
plete measurement tasks and thus HRQOL values must be
estimated by proxy assessors18.
At the time of this study, no studies have used the brief
and well established EQ-5D to estimate the HRQOL of T1DM
patients or their caregivers in Spain. The EQ-5D is a preferen-
ces-weighted instrument that incorporates utility values for
health outcomes and that can be used in cost–effectiveness
analyses to aid resource allocation decisions19.
The objective of this study was to cover this gap in meas-
uring and analyzing the HRQOL of T1DM pediatric patients
and their caregivers. Furthermore, we examined whether the
proxy version of the EQ-5D would be feasible and valid for
assessment of HRQOL among pediatric patients with T1DM.
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Research design and subjects
The CHRYSTAL study (Costs and Health Related qualitY of life
Study for Type 1 diAbetes meLlitus pediatric patients in
Spain) was a multicenter, cross-sectional, observational study
of pediatric patients diagnosed with T1DM who received out-
patient care in pediatric endocrinology specialized centers
within the healthcare system in Spain. The study followed
the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines20. Patients under 18 years
of age who had been diagnosed with T1DM for at least
12months were eligible for inclusion. Patients diagnosed
with any other type of diabetes, patients participating in clin-
ical trials and inpatients were excluded. The patient’s primary
caregiver was defined as the adult responsible for controlling
the patient’s diabetes most of the time (usually the mother
or father). Caregivers provided their informed consent to par-
ticipate in the study and to release information, and the
study was approved by the hospitals’ ethics committees in
accordance with national and regional regulations.
Study population
The number of patients to enroll was estimated according to
the distribution of pediatric patients with T1DM in Spain21.
We randomly selected 12 centers across Spain and the
researchers randomly selected patients fulfilling the inclusion
criteria. More information about the study population selec-
tion can be found in Lopez-Bastida and co-authors22.
Data collection
Data were collected between May and August 2014, at one
single time for each patient, by the investigators of each
center (pediatric endocrinologists or diabetes specialist
nurses). A Case Report Form (CRF) was completed by the
investigator using the patient’s medical record and one ques-
tionnaire was completed by the patient’s primary caregiver.
The CRF included the patient’s demographics (e.g. sex, age,
height, weight), clinical indicators for T1DM control (e.g.
HbA1c level), and diabetes-related complications and comor-
bidities (DCC) not including hypoglycemia but including
ketosis without acidosis, ketoacidosis, dawn phenomenon,
retinopathy, nephropathy, peripheral neuropathy, hypothy-
roidism and celiac disease.
Caregivers completed three questionnaires: the EQ-5D-3L
proxy version, the EQ-5D-5L and the Diabetes Module of the
Pediatric Quality of Life Inventory (PedsQL) (2–7 years old).
Patients completed two questionnaires: EQ-5D young version
(EQ-5D-Y) (8–17 years old) and PedsQL (8–17 years old).
Questionnaire (EQ-5D)
The EQ-5D is a simple generic instrument developed by a
multidisciplinary group of researchers23. This questionnaire has
been validated in many countries in Europe, including Spain,
and it is commonly used in economic evaluation and technol-
ogy assessment19. There are five dimensions in the EQ-5D
covering the areas of mobility, self-care, daily activities, pain/
discomfort and anxiety/depression. Evaluations of these health
states have been performed for the general population using
the time-trade-off method24. Health-state classification systems
like the EQ-5D provide an indirect means of obtaining prefer-
ence scores: patients and caregivers are assigned an EQ-5D
classification based on responses to the questionnaire, and
the validated preference scores are applied. The second part
of the EQ-5D consists of a vertical 20 cm, 0–100 visual ana-
logue scale (VAS), where 0 represents the worst and 100 rep-
resents the best imaginable health state. Respondents mark a
point on the scale to reflect their overall self-perception of
health on the day of the interview.
Caregivers assessed patients’ HRQOL as proxy respondents
using the EQ-5D-3L proxy version and also assessed their own
HRQOL through the EQ-5D-5L instrument, which has been vali-
dated in Spain25. The EQ-5D-3L proxy version questionnaire
included a standard proxy version of the EQ-5D, which asked
caregivers how they would rate their child’s health. We also
assessed patients’ HRQOL using the EQ-5D-Y in children aged
8years old or over. The EQ-5D-Y is a generic measure of health
status in children and young people with a design architecture
analogous to that of the original three-level version of EQ-5D
(EQ-5D-3L) used with adults26. The practical feasibility and valid-
ity of EQ-5D-Y has been demonstrated in several studies27–29;
however, there is currently no recommended value set to
derive a utility score from the EQ-5D-Y profile.
Other health status measure (PedsQL)
The PedsQL measures diabetes-specific HRQOL in the popu-
lation under 18 years of age. The PedsQL is a validated
HRQOL pediatric instrument for the Spanish speaking popu-
lation in Spain30–31. Its recall period is 7 days, and it is com-
posed of 5 dimensions comprising 28 items: “Diabetes
symptoms” (11 items), “Treatment 1” or treatment barriers (4
items), “Treatment 2” or treatment adherence (7 items),
“Worry” (3 items) and “Communication” (3 items). All items
are graded on a 5 point Likert scale from 0 (Never) to 4
(Almost always). Dimension scores are obtained as the mean
of items and the total score is the mean of dimension scores
which are converted to a 0 to 100 scale, where higher scores
indicate lower problems and higher HRQOL. The PedsQL
questionnaire was self-administered to patients aged 8 to 17
and completed by the principal caregiver for children aged 2
to 7, using the appropriate available age versions (ages 2–4,
5–7, 8–12 and 13–18). No instrument is available for patients
under 2 years of age and therefore these patients were
excluded from analysis of HRQOL.
Statistical analysis
All continuous variables were summarized by mean and
standard deviation. Usual tests for normality were applied
and we used ordinary least squares to assess the relationship
between the HRQOL and HbA1c level or the presence of
DCC. In the models, we included sex and age as control vari-
ables. Moreover, we estimated the correlations between
the PedsQL and the EQ-5D instruments, both the proxy
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(EQ-5D-3L) and the self-reported (EQ-5D-Y) versions, using
Spearman’s rank correlation coefficient (rho). According to
Cohen32, correlation coefficients with values from 0.1 to 0.29
were assumed low, from 0.3 to 0.49 moderate and 0.5 and
above were assumed high.
Results
A total of 267 patients and their caregivers were included for
analysis (97% of total sample); 8 were excluded because of
incomplete information for calculating HRQOL. Only 194
patients could complete the EQ-5D young version due to
age restrictions. The main characteristics of patients and their
caregivers are shown in Table 1.
As shown in Table 2, the results of the proxy version (EQ-
5D-3L) by HRQOL dimension revealed that, according to their
caregiver’s perception, 17.7% of children (n¼ 47) suffered
moderate pain or discomfort, 13.2% (n¼ 35) felt anxiety or
mild depression, 9.7% (n¼ 26) had some trouble carrying out
daily activities, and only one child (0.4%) had some trouble
dressing or washing themselves. The results of EQ-5D-Y,
completed by children 8 years old and over, showed that
21.0% of children suffered moderate pain or discomfort
(n¼ 41), 19.1% felt moderate anxiety or depression (n¼ 37),
6.7% had problems carrying out daily activities (n¼ 13), and
1.5% had some trouble getting dressed or washing
alone (n¼ 3).
Table 3 shows the HRQOL by HbA1c level and by pres-
ence of DCC in the past year according to the PedsQL instru-
ment. HRQOL was numerically higher in children with better
glycemic control, but no statistical significance was observed.
Likewise, better HRQOL was observed in children with no
presence of DCC.
The results of the EQ-5D-3L (proxy version) and the EQ-
5D-5L (caregivers’ self-administered instrument) showed that
the mean utility index scores were 0.95 and 0.92, respect-
ively, and the mean VAS scores were 86.1 and 81.8, respect-
ively (Table 1). The VAS scores varied significantly depending
on HbA1c level for both pediatric patients and caregivers,
with VAS scores significantly higher for HbA1c <7.5%.
However, both children (proxy responses) and caregivers
reported similar mean utility index scores by HbA1c level. By
DCC category (DCC versus no DCC), mean index scores for
patients were statistically different (0.91 and 0.96 respect-
ively) as per the proxy questionnaire. In the case of care-
givers, the mean VAS score was statistically higher when
children had no DCC.
Table 1. Patient and caregiver characteristics and HRQOL.
HbA1c level Presence of DCC All sample
HbA1c <7.5% (n¼ 159) HbA1c 7.5% (n¼ 108) No (n¼ 209) Yes (n¼ 58) Total (n¼ 267)
Patient characteristics
Patient age, mean (SD) 10.5 (3.9) 11.7 (3.9) 10.8 (4.0) 11.9 (3.4) 11.0 (3.9)
Time since diagnosis (years) 4.8 (3.2) 5.4 (3.3) 4.9 (3.2) 5.3 (3.4) 5.0 (3.2)
Sex (% male) 52.8 53.7 56.0 43.1 53.2
HbA1C last measurement, mean (SD) 6.8 (0.4) 8.3 (0.8) 7.3 (0.8) 7.7 (1.3) 7.4 (0.9)
HRQOL of patients
EQ-5D-3L proxy (VAS) 88.0 (12.9) 83.3 (14.0) 86.8 (13.1) 83.6 (15.0) 86.1 (13.6)
EQ-5D-3L proxy (index score) 0.95 (0.13) 0.94 (0.11) 0.96 (0.11) 0.91 (0.15) 0.95 (0.12)
EQ-5D-3L young (VAS) 89.2 (12.6) 82.8 (14.3) 87.2 (13.0) 83.7 (15.4) 86.4 (13.7)
Caregiver characteristics
Caregiver age, mean (SD) 42.1 (6.6) 42.9 (6.5) 42.2 (6.6) 43.3 (6.2) 42.4 (6.6)
Sex (% male) 20.1 14.8 19.1 13.8 18.0
HRQOL of caregivers
EQ-5D-5L (VAS) 83.5 (15.4) 79.4 (15.7) 82.8 (15.2) 78.3 (16.7) 81.8 (15.6)
EQ-5D-5L (index score) 0.92 (0.13) 0.91 (0.14) 0.92 (0.14) 0.90 (0.12) 0.92 (0.14)
Abbreviations. DCC, Diabetes-related complications and comorbidities; HRQOL, Health-related quality of life; SD, Standard deviation; VAS, Visual analog scale.
Bold text represents a statistically significant difference (p< .05 in the two-sided test of equality for column mean, t-test, or v2 z-test) between categories in
each group (HbA1c level, presence of DCC).
Table 2. HRQOL by dimension (EQ-5D scales).
EQ-5D dimension EQ-5D-level EQ-5D-3L (Proxy) n¼ 267 EQ-5D-Y (Young) n¼ 194
Mobility No problems in walking about 98.9% 97.4%
Some problems in walking about 1.1% 2.1%
Confined to bed 0.0% 0.5%
Self-care No problems with self-care 98.9% 97.9%
Some problems washing or dressing himself/herself 0.4% 1.5%
Unable to wash or dress himself/herself 0.8% 0.5%
Daily activities No problems with performing usual activities 89.5% 91.8%
Some problems with performing usual activities 9.7% 6.7%
Unable to perform usual activities 0.7% 1.5%
Pain/discomfort No pain or discomfort 82.3% 78.5%
Moderate pain or discomfort 17.7% 21.0%
Extreme pain or discomfort 0.0% 0.5%
Anxiety/depression Not anxious or depressed 85.3% 80.9%
Moderately anxious or depressed 13.2% 19.1%
Extremely anxious or depressed 1.5% 0.0%
Abbreviation. HRQOL, Health-related quality of life.
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The results of the regression models confirmed statistically
significant differences by HbA1c level in VAS results of the
EQ-5D of patients or caregivers after adjusting the differen-
ces by age and sex. The presence of DCC was also associated
with statistically lower HRQOL.
Correlations between the EQ-5D-3L proxy and PedsQL
The correlation between the different instruments used in
the study to estimate the HRQOL (EQ-5D scores and PedsQL
scales) was low to moderate (Table 4). Both the EQ-5D index
and the VAS scores were significantly correlated with several
age groups of the PedsQL. The highest correlation was
observed between the values of the VAS and the 13–17 year
old PedsQL age group (rho¼ 0.43; p< .001). The strongest
relationship between utility levels and PedsQL was observed
in children 5–7 years old, using the proxy utility values
(rho¼ 0.34; p¼ .016). Further correlations showed values
lower than 0.3, demonstrating a low to moderate correlation
between the different tools applied to assess the HRQOL.
Table 5 shows that the HRQOL of caregivers was corre-
lated with the HRQOL of children, with a rho¼ 0.55 (p¼ .02)
between the caregivers’ VAS and the PedsQL score of chil-
dren in the 2–4 year old age group (results by age group not
shown in table). Regardless of age, the correlation between
the HRQOL of caregivers and the PedsQL score for children
was rho¼ 0.19 (p¼ .003). On the other hand, correlation
between caregivers’ index scores and children’s index scores
measured through the EQ-5D-3L proxy version was moderate
(rho¼ 0.47; p< .001) (Table 5). Only a moderate
correlation was observed between the EQ-5D-Y version VAS
score (perception of HRQOL from children 8 and over) and
the EQ-5D-3L proxy version VAS score (perception of the
HRQOL from caregivers of children 8 and above) with a
rho¼ 0.45 (p< .001).
Discussion
This is the first study to assess HRQOL in T1DM pediatric
patients and their caregivers in Spain. Our results show that
HRQOL is mainly affected by the pain/discomfort and depres-
sion/anxiety dimensions in patients and caregivers. Mean
utility index scores were 0.95 and 0.92 for children (proxy
measurement) and caregivers (self-assessment), respectively.
It is important to note that it is unknown whether question-
naires for patients and caregivers were completed independ-
ently of each other; a factor which could influence the
concordance of the results. Data from the Spanish National
Health Survey 2011–2012 indicate that the mean utility index
score of the general population in the same age range as
Table 3. Patient HRQOL according to the PedsQL instrument/questionnaire.
HbA1c level, mean (SD), n Presence of DCC, mean (SD), n Total (n¼ 228)
HbA1c <7.5% HbA1c 7.5% No Yes
PedsQL (2–4)
n¼ 18
70.5 (14.5), 9 65.7 (11.0), 9 67.5 (12.9), 17 77.7a 68.1 (12.7)
PedsQL (3–7)
n¼ 50
70.6 (14.1), 35 64.9 (12.3), 15 68.7 (13.5), 39 69.6 (15.4), 11 68.9 (13.8)
PedsQL (8–12)
n¼ 89
72.2 (11.1), 60 71.5 (15.9), 29 72.9 (12.5), 68 69.0 (13.5), 21 72.0 (12.8)
PedsQL (13–17)
n¼ 103
74.6 (12.9), 50 71.8 (12.0), 53 74.4 (12.4), 79 68.8 (11.9), 24 73.1 (12.5)
PedsQL (all ages)
n¼ 260
72.5 (12.6), 154 70.2 (13.3), 106 72.2 (12.8), 203 69.2 (13.0), 57 71.6 (12.9)
aOnly one patient in the 2–4 age group had diabetes-related complications.
Abbreviations. DCC, Diabetes-related complications and/or comorbidities; HRQOL, Health-related quality of life; PedsQL, Diabetes module of the Pediatric Quality
of Life Inventory; SD, Standard deviation.
Table 4. Correlations between HRQOL of the children, measured through PedsQL and EQ-5D questionnaires.
Children’s HRQOL (PedsQL) EQ-5D-Y: VAS EQ-5D proxy version: VAS EQ-5D proxy version: utility index
Age 2–4 (n¼ 18) – 0.35 (p¼ .16) 0.21 (p¼ .43)
Age 5–7 (n¼ 50) – 0.22 (p¼ .12) 0.34 (p5 .02)
Age 8–12 (n¼ 89) 0.29 (p5 .006) 0.11 (p¼ .31) 0.17 (p¼ .12)
Age 13–17 (n¼ 103) 0.43 (p< .001) 0.26 (p5 .008) 0.17 (p¼ .08)
All ages (n¼ 260) 0.33 (p< .001) 0.22 (p< .001) 0.20 (p5 .002)
Abbreviations. HRQOL, Health-related quality of life; PedsQL, Diabetes module of the Pediatric Quality of Life Inventory; VAS, Visual analogue scale.
Bold text indicates statistical significance. Values between 0.1 and 0.29 indicate low correlation, between 0.3 and 0.49 moderate correlation and equal to or
above 0.5 high correlation.
Table 5. Correlations between HRQOL of caregivers and HRQOL of children.
Caregivers’ HRQOL (EQ-5D-5L) EQ-5D-Y: VAS PedsQL (all ages) EQ-5D-3L proxy version: utility index
VAS 0.25 (p5 .001) 0.19 (p5 .003) 0.30 (p< .001)
Index score 0.47 (p< .001)
Abbreviations. HRQOL, Health-related quality of life; PedsQL, Diabetes module of the Pediatric Quality of Life Inventory; VAS, Visual analogue scale.
Bold text indicates statistical significance. HRQOL of the caregivers was measured through the EQ-5D-5L; HRQOL of the children was measured through the
PedsQL questionnaire and EQ-5D questionnaires (EQ-5D-Y and EQ-5D-3L proxy).
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the caregivers in our sample was 0.96. Therefore, caregivers
of children diagnosed with T1DM experience a slightly lower
HRQOL relative to the general population. However, care-
givers have a HRQOL similar to that of the general popula-
tion after controlling for age33.
As studies conducted in the United States have found34,
HRQOL of both patients and caregivers is negatively affected
by poor glycemic control and by the presence of DCC. The
EQ-5D has not been used frequently to assess HRQOL of dia-
betic children in previous research9. The few pediatric studies
that have used this instrument have focused on medical con-
ditions including asthma, hemophilia and congenital anorec-
tal malformations18,35,36. Use of the EQ-5D instrument has
the advantage that it is a generic questionnaire, which allows
researchers to elicit utilities which can then be used in cost-
effectiveness analyses. While it was developed for an adult
population and is meant to be self-reported, some studies
have used the EQ-5D in parent-proxy ratings and have
shown it to be both feasible and valid37,38. Differences in
utilities in patients with T1DM by age, self-reported versus
proxy reported and elicitation method raise important ques-
tions about whose utilities should be used in eco-
nomic analyses34.
There is considerable debate in the literature about
whether proxies can be used to estimate the HRQOL of chil-
dren with T1DM and no clear consensus has been found.
The use of proxies has been justified due to the lack of ver-
bal capacity of the children being evaluated39.
The current study builds on this previous research by sug-
gesting that the EQ-5D is also a feasible and valid brief
measure of HRQOL among pediatric patients with T1DM. All
caregivers in this study were able to rate their children on
the five dimensions of the EQ-5D, and scores reflected the
moderate level of impairment that would be expected in
this population.
Construct validity of the EQ-5D was demonstrated
through statistically significant correlations with HRQOL
domains as assessed by multi-item scales of the PedsQL and
the EQ-5D-Y and VAS score. The use of VAS provides a com-
plementary score to the descriptive system of the self-assess-
ment of the health status of the patients. However, without
the descriptive system we do not know which dimension of
health is affected.
These findings suggest that the brief, proxy version of the
EQ-5D may be used among parents of children and adoles-
cents with T1DM to obtain an estimate of the child’s HRQOL
when it is not feasible to administer a longer parent-reported
HRQOL instrument. Statistically significant correlations were
also found between the EQ-5D and the PedsQL, suggesting
that PedsQL symptoms and their impact likely contributed to
parents’ proxy EQ-5D ratings.
There are a number of limitations to note. Firstly, this was
a cross-sectional study: one-time assessments in T1DM can
be influenced by the inherent variations of assessment con-
ditions on a particular day. Future researchers might conduct
longitudinal assessments to monitor changes in patients’ and
caregivers’ utility scores and to test the ability of the
measures to predict health service utilization, as worsening
utilities are associated with higher resource utilization.
Secondly, there is the possibility of misrepresentation
when assigning health status to children. As concluded else-
where, the values for health states when ascribed to adults
are higher than when those same states are ascribed to chil-
dren40. Finally, there may also be questions about the repre-
sentativeness of the sample, as patients were drawn from
selected sites and most had employed caregivers. Although
sites were selected randomly, patients or families with social
or economic problems which may lead to less compliance
with medical appointments may be under-represented.
Conclusions
The findings of this study illustrate opportunities and chal-
lenges in measuring HRQOL in T1DM pediatric patients.
Caregivers seemed willing and able to complete the EQ-5D
questionnaires as proxies. Moreover, the EQ-5D discriminated
well among T1DM severity. The results reveal the extensive
consequences of T1DM on pediatric patients and could
potentially be used in cost–effectiveness analyses of pharma-
cologic and non-pharmacologic interventions in T1DM. The
data suggest that utility scores for caregivers may worsen
slightly for patients with Hb1Ac 7.5% and DCC.
This is the first study to assess HRQOL in T1DM pediatric
patients and their caregivers in Spain with different generic
and specific validated questionnaires. The results of this
study provide baseline information about HRQOL in pediatric
T1DM in Spain. Patients with few DCC and well controlled
HbA1c reported a relatively high HRQOL. This information
will help evaluate the effectiveness of further intervention
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